Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients

Inclusion Criteria: * Female, 20 to 65 years of age * Diagnosed with breast cancer stage Ⅰ-Ⅲ, and have completed cancer treatment including breast surgery and/or adjuvant chemotherapy, radiotherapy, hormonal therapy * BMI ≥25 kg/m2, or BMI ≥23 kg/m2 with one or more of the metabolic risk factors (waist circumference ≥80 cm, fasting glucose ≥100 mg/dL, BP ≥130/85 mmHg, HDL-cholesterol \<50 mg/dL or controlled diabetes, hypertension, dyslipidemia with medications) * If woman of child bearing potential, agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug * Able to speak and read Korean * Able to comply with all required study procedures and schedule * Willing and able to give written informed consent Exclusion Criteria: * Participants with cancer recurrence or metastasis * Participants with uncontrolled hypertension (systolic blood pressure (SBP) \>180 mmHg, or diastolic blood pressure (DBP) \>120 mmHg) * Participants with hepatic disease (aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \>3 x institutional upper limit of normal) or renal disease (serum creatinine \>2.0 mg/dL) * Participants with significant cardiovascular disease or stroke * Participants with history of seizures * Participants with serious psychiatric illness, including bipolar disorder, schizophrenia, or other psychosis, bulimia, anorexia nervosa, or suicidal ideation * Participants who are taking medications such as monoamine oxidase (MAO) inhibitors, opioid-containing medications, other naltrexone or bupropion containing medications, and Tamoxifen * Current smokers or use of nicotine replacement products in the previous 6 months * Pregnant or breast-feeding women * Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in this study